Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

Item
http://www.wikidata.org/entity/Q24202199
Trastuzumab-containing regimens for metastatic breast cancerTargeted drugs and Psycho-oncological intervention for breast cancer patientsHealth economic aspects of breast cancer treatment: the compulsory health insurances' viewAGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast CancerStandard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapySystematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.Contrast-Enhanced Ultrasonography Features of Breast Malignancies with Different Sizes: Correlation with Prognostic FactorsDNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
P2860

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

Item
http://www.wikidata.org/entity/Q24202199
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@ast
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en-gb
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@nl
type
label
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@ast
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en-gb
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@nl
prefLabel
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@ast
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en-gb
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@nl
P1433
P1476
P2093
P2860
P31
P3181
P356
P50
P577
P5875
P698
P921
P3181
P356
P1433
P1476
Vascular-endothelial-growth-fa ...... stant metastatic breast cancer
@en
P2093
P2860
P31
P3181
P356
10.1002/14651858.CD008941.PUB2
P50
P577
P5875
P698
P921